To amend the Federal Food, Drug, and Cosmetic Act to provide a period of market exclusivity for botanical drugs, and for other purposes.
Summary
HR10150, introduced by Rep. Boebert, proposes market exclusivity for FDA-approved botanical drugs. The bill is in early committee stage with low legislative momentum and no specified funding. No direct market impact is expected at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR10150 is an early-stage bill with low legislative momentum.
- 2.No funding is authorized; the bill creates a regulatory exclusivity framework.
- 3.No specific tickers can be confidently identified as beneficiaries at this stage.
Market Implications
No immediate implications for publicly traded companies. The bill is too early in the legislative process to drive sector-wide movements. If the bill advances, companies with FDA-approved botanical drugs (e.g., Jazz Pharmaceuticals' Epidiolex) could see enhanced revenue visibility, but such a scenario is speculative.
Full Analysis
On August 27, 2026, Rep. Lauren Boebert (R-CO) introduced HR10150, a bill to amend the Federal Food, Drug, and Cosmetic Act to provide a period of market exclusivity for botanical drugs. The bill was referred to the House Committee on Energy and Commerce, which has jurisdiction over FDA regulation. As of the analysis date, the bill has one cosponsor (Rep. Van Orden) and has seen no further action. The sponsor is a junior member of the House, not a committee chair, indicating limited legislative momentum. The bill does not authorize any specific funding; it creates a regulatory incentive (market exclusivity) similar to orphan drug exclusivity. The mechanism would apply to botanical drugs that receive FDA approval, potentially encouraging R&D in plant-based therapeutics. However, the bill is at an early stage—referred to committee—and faces a long path to enactment. No companion bill has been introduced in the Senate. Given the procedural status and narrow scope, the near-term market impact is negligible. Investors should monitor for committee hearings or markup sessions, which would signal increased probability of advancement. No specific publicly traded companies are directly and confidently tied to this bill at this stage, as the botanical drug sector is fragmented and largely composed of private or pre-revenue firms.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
HUMAN SERVICES, NEW JERSEY DEPARTMENT OF: $16.9B Department of Health and Human Services Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
DEPARTMENT OF SOCIAL SERVICES MISSO: $15.1B Department of Health and Human Services Grant
MINNESOTA DEPARTMENT OF HUMAN SERVICES: $14.1B Department of Health and Human Services Grant
GEORGIA EMERGENCY MANAGEMENT AND HOMELAND SECURITY AGENCY: $1.6B Department of Homeland Security Grant
MARYLAND DEPARTMENT OF HEALTH: $11.5B Department of Health and Human Services Grant
OKLAHOMA HEALTH CARE AUTHORITY: $8.2B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →